Evidence map›Paper›PMID 35615265›Full record

ArticleMolecular therapy oncolytics2022

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models.

Masahiko Hatta, Masaki Kaibori, Hideyuki Matsushima, Terufumi Yoshida, Tadayoshi Okumura, Mikio Hayashi, Kengo Yoshii, Tomoki Todo, Mitsugu Sekimoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. New strategies in soft tissue sarcoma treatment.Journal of hematology & oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Masahiko HattaDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Masaki KaiboriDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Hideyuki MatsushimaDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Terufumi YoshidaDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Tadayoshi OkumuraDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Mikio HayashiDepartment of Cell Physiology, Institute of Biomedical Science, Kansai Medical University, Hirakata, Japan.
Kengo YoshiiDepartment of Medical Statistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tomoki TodoDivision of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
Kansai Medical University · JPKyoto Prefectural University of Medicine · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant soft tissue tumors, particularly highly malignant leiomyosarcomas, are resistant to chemotherapy and associated with a poor prognosis. T-01, a third-generation genetically modified herpes simplex virus type 1, replicates in tumor cells alone and exerts a cell-killing effect. The current study aimed to investigate the antitumor effect of T-01, which is a novel treatment for leiomyosarcoma.

Indexed as

herpes simplex virusmalignant soft tissue tumormouse xenograft modeloncolytic virusT-01

Identifiers

PMID35615265
PMCPMC9118137
OpenAlexW4224839124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.